AVITA Medical, Inc. (RCEL)

$9.23

+0.54 (+6.21%)
Rating:
Recommendation:
-
Symbol RCEL
Price $9.23
Beta 0.918
Volume Avg. 0.08M
Market Cap 231.035M
Shares () -
52 Week Range 4.41-11.0
1y Target Est -
DCF Unlevered RCEL DCF ->
DCF Levered RCEL LDCF ->
ROE -30.57% Strong Sell
ROA -29.81% Sell
Operating Margin -
Debt / Equity 13.58% Neutral
P/E -
P/B 2.62 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest RCEL news


Dr. Michael S. Perry D.V.M., DVM, Ph.D., FACVPT
Healthcare
Medical Devices
NASDAQ Capital Market

AVITA Medical, Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's skin to use in the treatment of acute thermal burns in patients eighteen years and older. AVITA Medical, Inc. has a research agreement with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. was incorporated in 2000 and is based in Valencia, California.